All In Biotech

Drug Trial Radar · NCT01773187

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Last checked: Nov 20, 2026Latest source record: Sep 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 327 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

327

Actual

Start

Jan 2013

Primary completion

Jan 2015

Study completion Apr 2016

Sponsor

Lead sponsor
CTI BioPharmaIndustry
Sponsor type
Industry
First posted
Jan 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.

Conditions

  • Primary Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Interventions

  • PacritinibDrug

  • Best Available TherapyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Spleen Volume ReductionTime frame: Baseline to Week 24

Locations

81 sites in 12 countries. Site status is shown where the registry gives one.

  • CTI Investigational Site 10002

    Scottsdale, Arizona

  • CTI Investigational Site 10004

    Omaha, Nebraska

  • CTI Investigational Site 10001

    Morristown, New Jersey

  • CTI Investigational Site 10003

    Greenville, South Carolina

  • CTI Investigational Site 61006

    Box Hill, Australia

  • CTI Investigational Site 61001

    Coffs Harbour, Australia

  • CTI Investigational Site 61005

    Geelong, Australia

  • CTI Investigational Site 61003

    Gosford, Australia

  • CTI Investigational Site 61004

    Hobart, Australia

  • CTI Investigational Site 61002

    Milton, Australia

  • CTI Investigational Site 32002

    Antwerp, Belgium

  • CTI Investigational Site 32003

    Antwerp, Belgium

  • CTI Investigational Site 32001

    Bruges, Belgium

  • CTI Investigational Site 32005

    Brussels, Belgium

  • CTI Investigational Site 32004

    La Louvière, Belgium

  • CTI Investigational Site 42003

    Brno, Czechia

  • CTI Investigational Site 42001

    Olomouc, Czechia

  • CTI Investigational Site 42002

    Pilsen, Czechia

  • CTI Investigational Site 42004

    Prague, Czechia

  • CTI Investigational Site 33005

    Amiens, France

  • CTI Investigational Site 33006

    Caen, France

  • CTI Investigational Site 33011

    Grenoble, France

  • CTI Investigational Site 33012

    Lens, France

  • CTI Investigational Site 33007

    Lille, France

  • CTI Investigational Site 33001

    Nîmes, France

  • CTI Investigational Site 33004

    Paris, France

  • CTI Investigational Site 33008

    Paris, France

  • CTI Investigational Site 33009

    Pessac, France

  • CTI Investigational Site 33010

    Pierre-Bénite, France

  • CTI Investigational Site 33003

    Strasbourg, France

  • CTI Investigational Site 33002

    Toulouse, France

  • CTI Investigational Site 49006

    Berlin, Germany

  • CTI Investigational Site 49007

    Berlin, Germany

  • CTI Investigational Site 49001

    Cologne, Germany

  • CTI Investigational Site 49003

    Dresden, Germany

  • CTI Investigational Site 49008

    Essen, Germany

  • CTI Investigational Site 49002

    Freiburg im Breisgau, Germany

  • CTI Investigational Site 49005

    Mainz, Germany

  • CTI Investigational Site 49004

    München, Germany

  • CTI Investigational Site 49009

    Münster, Germany

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.